Logo Image
Opinion|Videos|July 12, 2024

Highlights from ASCO 2024: Individualized Neoantigen Therapy in Melanoma

Considerations for neoantigen therapy tailored to specific patient needs is discussed by Dr Lipson.

Episodes in this series

Video content above is prompted by the following:

  • Discuss the 3-year updated data presented at ASCO 2024 on individualized neoantigen therapy (mRNA-4157) plus pembrolizumab in resected melanoma.
    • What was the objective of this study?
    • How was this study designed/what methodology was used?
    • What results were presented?
  • Please provide your key takeaways from this study. How might these findings impact the management of patients with melanoma?

Related Content